ArticleOncotarget2017
Inhibition of autoimmune Th17 cell responses by pain killer ketamine.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study.Translational psychiatry · 2025Trial
- Association of plasma cytokines and antidepressant response following mild-intensity whole-body hyperthermia in major depressive disorder.Translational psychiatry · 2023Trial
- Impact of prolonged isoflurane or ketamine-xylazine anesthesia with or without buprenorphine and oxygen on mouse vitals and immune responses.Lab animal · 2025Article
- Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects?Molecular psychiatry · 2024Review
- Review
- Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.Neuronal signaling · 2023Review
- Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.Drug discovery today · 2023Review
- Ketamine induces apical extracellular matrix modifications in Caenorhabditis elegans.Scientific reports · 2022Article
- Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells.Pharmacological reviews · 2022Review
- Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.Cellular and molecular life sciences : CMLS · 2021Review
- Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?Frontiers in pharmacology · 2021Review
- Sepsis impedes EAE disease development and diminishes autoantigen-specific naive CD4 T cells.eLife · 2020Article
- Ketamine in Bipolar Disorder: A Review.Neuropsychiatric disease and treatment · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine is widely used in animals and humans as a systemic anesthetic. Although several immune-modulatory functions of ketamine have been reported, the effects of ketamine on the differentiation of Th17 cell are unknown. We found that ketamine significantly diminished the frequency of IL-17-producers among CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.